Ongoing Clinical Trials & Studies

Endo provides required updates around ongoing clinical trials on www.clinicaltrials.gov. To access additional detail about these studies please visit the links provided below.

For inquiries about our ongoing clinical trials, please contact us at clinicaltrials@endo.com.

Medical Therapeutics

Study ID

Study Description

Intervention

Study Phase/Type

Recruitment Status* / ClinicalTrials.gov Identifier (if applicable)
EN3835-306 A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis. Collagenase clostridium histolyticum EN3835 Phase 3/ Rollover  Active, no longer recruiting.
New Window

NCT05254457

EN3835-227 PFA A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Assess The Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA) Collagenase clostridium histolyticum EN3835 Phase 2/ Interventional Recruiting
New Window

NCT06169319

EN3835-309 PFI A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI) Collagenase clostridium histolyticum EN3835 Phase 3/ Interventional Recruiting
New Window

NCT06151197

EP02REG Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease (CURVE-PD) None Registry Recruiting
New Window

NCT06151197

EP01REG Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture (GRASP-DC) None Registry Recruiting
New Window

NCT05877066

 newWindow_gray.png By clicking on the link(s) on this page you will leave the Endo.com website and move to an external website(s) independently operated and not managed by Endo Pharmaceuticals. Because Endo Pharmaceuticals does not control the content of the website(s) you are about to visit, and due to its constantly changing nature, we cannot be responsible for its content, accuracy, practices, or standards.

US/RD/CORP/2014/00002a 5/2014